Ro48-6791

Ro48-6791

Systematic (IUPAC) name
3-{5-[(dipropylamino)methyl]- 1,2,4-oxadiazol-3-yl}- 8-fluoro- 5-methyl- 4,5-dihydro- 6H-imidazo[1,5-a] [1,4]benzodiazepin- 6-one
Identifiers
CAS Registry Number
PubChem	CID:
Chemical data
Formula	C21H25FN6O2
Molecular mass	412.47
Y

Ro48-6791 is a drug, a benzodiazepine derivative developed by Hoffman-LaRoche in the 1990s.^[1]

Ro48-6791 was developed as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures. Ro48-6791 has properties similar to those of to midazolam, being water-soluble, with a fast onset and short duration of action. It is 4-6x more potent than midazolam,^[2] and slightly shorter acting,^[3] and produces similar side effects such as sedation and amnesia.

It was tested up to Phase II human trials, but while it produced less respiratory depression than propofol, it had a longer recovery time and was deemed not to have any significant advantages over the older drug.^[4] Similarly when Ro48-6791 was compared to midazolam, it had similar efficacy, higher potency and a shorter recovery time, but produced less of a synergistic effect on opioid-induced analgesia and produced more severe side effects such as dizziness after the procedure.^[5] Consequently, it was dropped from clinical development,^[6] although it is still used in scientific research.^[7]

See also

• Benzodiazepine

References